GlassScriptPhysician profile
Donald P Patterson
NPI 1053306175
$7,762.14
in general payments reported to CMS, 2019-2025
42 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $1,012 · 2021: $269 · 2022: $579 · 2023: $1,198 · 2024: $1,385 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,307.10 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,242.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,057.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $843.72 | 2019-2025 | Farxiga, Tezspire |
| Amgen INC. | $546.77 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $545.87 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.97 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $517.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $432.06 | 2020-2025 | |
| Glaxosmithkline, LLC. | $261.12 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $207.89 | 2019-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $195.75 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $181.88 | 2019-2020 | |
| Exact Sciences Corporation | $118.32 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $117.86 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.02 | 2019-2023 | Trintellix |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.